ALGS
Aligos Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$35.64M
P/E Ratio
—
EPS
$-9.78
Beta
2.28
52W High
$13.69
52W Low
$5.12
50-Day MA
$6.81
200-Day MA
$8.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $4.71M |
| Gross Profit (TTM) | $-64.75M |
| EBITDA | $-94.59M |
| Operating Margin | -952.00% |
| Return on Equity | -121.90% |
| Return on Assets | -55.60% |
| Revenue/Share (TTM) | $0.45 |
| Book Value | $5.14 |
| Price-to-Book | 1.13 |
| Price-to-Sales (TTM) | 7.58 |
| EV/Revenue | 0.477 |
| EV/EBITDA | 0.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 810.00% |
| Shares Outstanding | $5.39M |
| Float | $3.64M |
| % Insiders | 10.30% |
| % Institutions | 55.08% |
Historical Volatility
HV 10-Day
105.15%
HV 20-Day
84.91%
HV 30-Day
97.90%
HV 60-Day
83.53%
HV Rank
79.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($58.17 target)
1
Strong Buy4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026